CDK4 and synovial sarcoma: Synovial sarcoma cells treated with non-lethal doses of palbociclib unveiled that CDK4 inhibition reduced synovial sarcoma cell migration, suggesting that CDK4 might be a promotor to synovial sarcoma metastasis, which is the main obstacle in the treatment of synovial sarcoma.